Centene Class Action Lawsuit: Breaking: Centene Faces a Staggering and Turbo-charged Class Action Lawsuit Over Medicare Claims while Investor Portfolios Take a Shellacking [2025]

The Centene Lawsuit, now known as Lunstrum v. Centene Corporation, has been filed in the Southern District of New York. The company and its executives stand accused of violating the Securities Exchange Act of 1934. The Centene Class Action Lawsuit highlights several issues:

• The company’s marketplace membership growth fell short of projections across 22 states, which makes up 72% of their total membership
• Centene had to lower its guidance to $1.8 billion, resulting in an adjusted diluted EPS of $2.75
• Health Net Federal Services and Centene Corporation have agreed to pay $11,253,400 to settle claims about falsely certified cybersecurity compliance in a separate case.

Investors affected by these issues need to act fast. The court’s deadline for filing lead plaintiff motions ends September 8, 2025. The situation looks even more concerning since Centene has withdrawn its guidance due to slower marketplace growth and higher morbidity rates.

Please see the various investor resources below for an additional wealth of information.

Lead Plaintiff Deadlines

Investor Resources

Frequently Asked Questions

Shareholder Rights

Report a Fraud

Investors File Massived Class Action Against Centene

A huge securities fraud class action lawsuit has emerged against Centene Corporation (NYSE: CNC). Investors want to recover substantial losses after the healthcare provider allegedly misled shareholders about enrollment figures and market health.

Lawsuit filed in Southern District of New York

The lawsuit, formally titled Lunstrum v. Centene Corporation, No. 25-cv-05659, has been filed in the U.S. District Court for the Southern District of New York. This legal action aims to represent investors who bought or acquired Centene securities between December 12, 2024, and June 30, 2025. The Centene Class Action Lawsuit accuses Centene and several top executives of violating the Securities Exchange Act of 1934.

The deadline to file motions as lead plaintiff is September 8, 2025.

Allegations tied to Medicare Advantage claims

The plaintiffs’ core allegations focus on misleading statements about:

1. Centene’s projected revenue outlook and predicted growth
2. Enrollment rates across Medicare programs
3. Market morbidity levels in serviced states

Centene’s executives allegedly created “the false impression that they possessed reliable information pertaining to [Centene’s] projected revenue outlook and predicted growth while also touting enrollment rates and low morbidity”. This positive narrative contradicted what was happening inside the company.

The Centene Class Action Lawsuit alleges that Centene hid crucial information about lower-than-predicted enrollment and increased total market morbidity in its Medicare programs. The company also faces other legal challenges, including a lawsuit it filed against CMS over Medicare Advantage star ratings.

Stock drop triggers investor losses

The truth came out on July 1, 2025, when Centene suddenly withdrew its 2025 financial guidance. This announcement came after analyzing the 2025 Health Insurance Marketplace. Market growth in 22 states—representing 72% of Centene’s marketplace membership—was substantially lower than projected.

On top of that, Wakely Consulting Group’s independent actuarial review confirmed these concerning trends. The company then reduced its guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75.

The market reacted quickly and harshly. Centene’s stock price dropped from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025—a devastating 40.4% single-day decline. This dramatic fall wiped out billions in shareholder value.

The financial impact continued beyond the original drop. Morgan Stanley downgraded Centene’s stock to “Equalweight” and cut its price target to $33.00, citing ongoing concerns about the company’s Medicaid and Commercial segments.

What Allegations Are Made in the Centene Lawsuit?

The Centene Class Action Lawsuit reveals several layers of alleged wrongdoing. Investors say the healthcare giant misled them about important financial numbers, hid unfavorable data, and managed to keep an artificially inflated stock price through late 2024 and early 2025.

Claims of misleading revenue guidance

Centene shareholders believe the company misled them about its financial future and revenue outlook. The main complaint points out that executives created a “false impression that they possessed reliable information pertaining to projected revenue outlook and predicted growth”. The alleged misrepresentations include:

1. On December 12, 2024, Centene announced 2025 adjusted diluted EPS guidance of “greater than $7.25,” showing over 6% year-over-year growth
2. The company expected 7.6% growth and “$11.00 billion of additional premium revenue” for 2025
3. These numbers crashed on July 1, 2025, when Centene cut guidance by about $1.80 billion, which meant an adjusted diluted EPS drop of roughly $2.75

The Centene Lawsuit states these “optimistic reports and promises regarding inflated guidance fell short of reality”. In fact, this dramatic guidance cut made the stock crash by 40.4%, dropping from $56.65 to $33.78 per share between July 1-2, 2025.

Discrepancies in Medicare enrollment data

The enrollment misrepresentations make up another big part of the Centene Class Action Lawsuit. Centene kept talking about “strong retention” and “favorable” enrollment trends during this period, but their internal data told a different story. The claims show:

• Centene hid that its “marketplace share showed lower-than-predicted enrollment“
• Internal numbers showed poor growth in 22 states that made up 72% of Centene’s marketplace membership
• They painted a rosy picture of Medicare Advantage enrollment while knowing the numbers were below expectations

The investors say they bought Centene securities at inflated prices based on false information. The Centene Class Action Lawsuit comes while Centene fights another legal battle with the federal government over Medicare Advantage star ratings, claiming a botched assessment could cost them $73 million in revenue.

Failure to disclose market morbidity trends

The most costly allegations center on Centene hiding unfavorable morbidity trends. The Centene Lawsuit states:

1. Centene didn’t tell investors about “rising disease prevalence in its markets,” which drove up costs and hurt profits
2. Their ACA business, which depends on federal risk-sharing, made less money than advertised because claims were higher than predicted
3. Wakely Actuarial Consulting’s independent study found that “enrollees were sicker than projected,” which cut expected risk-adjustment payments

Unlike their public statements, the Centene Class Action Lawsuit claims Centene’s internal data showed “increased combined market morbidity” that was “by a lot higher than, and materially inconsistent with” the numbers used for financial guidance.

The SEC now wants to know if Centene knew—or should have known—about these wrong assumptions while failing to tell investors about the risks. The most damaging claim suggests the company ignored red flags in states where rising healthcare costs already hurt their profits.

Who Can Join the Centene Class Action Lawsuit?

Centene’s stock plunge has severely hurt investors who now have a short time to seek legal remedies. Affected shareholders must quickly check if they qualify as the formal litigation moves forward.

Eligibility criteria for affected investors

Investors must meet specific requirements to join the Centene Class Action Lawsuit:

1. Purchase Timing: You must have purchased or acquired Centene Corporation securities during the designated class period.
2. Financial Impact: You must prove financial losses that directly resulted from the alleged securities fraud.
3. Documentation: You need complete purchase records to measure eligible losses.

Note that you don’t need to be a lead plaintiff to receive part of any potential recovery. Shareholders with smaller losses can also join the class action. Start by checking your investment records against the class period dates.

Timeframe for share purchases

The official class period runs for about six and a half months:

• Start Date: December 12, 2024
• End Date: June 30, 2025

The class action only covers shares bought or acquired during this timeframe. This period represents when Centene allegedly made misleading statements about its financial health before withdrawing guidance on July 1st, which caused the stock to collapse.

If you suffered substantial losses and wish to serve as lead plaintiff of the Centene Class Action Lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].

Deadline for lead plaintiff motion: September 8, 2025

Potential claimants must focus on September 8, 2025 – the deadline to file lead plaintiff motions with the court. This date falls on the first business day after 60 days from the notice of pendency publication.

You must meet these requirements to become lead plaintiff:

1. File a motion with the Southern District of New York court before the deadline
2. Show substantial financial losses
3. Demonstrate that your claims match those made for the class

The person who files the first complaint must publish a notice announcing the filing of a securities class action. Anyone who wants to serve as lead plaintiff must file their motion within 60 days.

You can still participate in any potential settlement or judgment as a class member even if you miss the lead plaintiff deadline or choose not to serve in that role.

How Will the Legal Process Unfold?

The Centene class action lawsuit will move through several distinct legal phases in the federal court system. This securities fraud litigation follows a well-laid-out process that balances investor rights with procedural safeguards.

Steps in a securities class action

Securities class actions like Centene Class Action Lawsuit follow a specific path:

1. Initial complaint filing – The first plaintiff files a complaint that alleges securities law violations
2. Publication of notice – A national business publication must carry the notice within 20 days to alert potential class members
3. Lead plaintiff selection – The court picks a lead plaintiff within 90 days after the notice appears
4. Consolidated complaint – The court combines multiple cases into a single complete complaint
5. Motion to dismiss – Defendants usually challenge the legal merit of claims
6. Discovery process – Document collection and witness testimony start after surviving dismissal
7. Class certification – The court decides if the case qualifies for class treatment
8. Potential settlement – Most cases end in negotiated settlements instead of going to trial

Importance of surviving motion to dismiss

The motion to dismiss stands as a vital milestone for the Centene Lawsuit. The Private Securities Litigation Reform Act (PSLRA) puts all discovery proceedings on hold during this time.

Defendants file these motions to end cases early because defending securities fraud lawsuits costs substantial money. Judge Maldonado’s recent ruling in another Centene case (Havrilla v. Centene Corp.) shows the significance of these early rulings. She let most claims continue after finding plaintiffs had “pled sufficient facts to allege a RICO conspiracy”.

Role of evidence and documentation

Evidence is the life-blood of securities fraud litigation. Centene’s affected investors should:

• Gather all financial statements, press releases, and analyst reports about the alleged misrepresentations
• Record their complete investment history with Centene, including dates, quantities, and prices
• Keep records organized by type and date so legal counsel can review them quickly

Good documentation makes both individual positions and the collective case stronger.

How law firms support investor claims

Many law firms now actively seek affected Centene investors. These firms offer significant support by:

1. Handling case logistics and court filings
2. Paying litigation costs upfront—shareholders usually pay nothing to start
3. Sending regular case updates and analysis
4. Working on contingency fees.

If you suffered substantial losses and wish to serve as lead plaintiff of the Centene Class Action Lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].

What Are the Potential Impacts on Centene?

The Centene Class Action Lawsuit has let loose a wave of changes that go way beyond the courtroom. These changes have touched every aspect of the healthcare giant’s operations, finances, and leadership structure.

Reputational damage and investor confidence

The company’s decision to withdraw guidance created panic in the investment community:

• The stock price took a nosedive, dropping over 40% and wiping out billions in shareholder value
• Morgan Stanley cut Centene’s rating to “Equalweight” with a reduced price target of $33.00
• Analysts keep raising red flags about Centene’s Medicaid and Commercial segments

Mr. Miles has also been recognized the last two years has been recognized as one of the Top-Rated Lawyers in Tennessee (Lawyers of Distinction 2021-2022). Thus, Mr. Miles brings a wealth of experience to your case as an experienced class action, mass tort, products liability, securities fraud, dangerous drugs and as a Nashville whistleblower attorney.

Possible financial penalties and settlements

The financial fallout goes far beyond the stock market crash:

1. The lawsuit seeks to recover $1.25 billion in damages for the represented class
2. The company paid close to $1 billion to settle cases across 22 states related to pharmacy benefit manager operations
3. CMS might increase its oversight, having previously found that Centene “failed substantially to carry out the terms of its contract”

The securities litigation is just one of Centene’s regulatory headaches. Florida health regulators slapped a $9 million fine on the company for wrongly denying claims of more than 121,000 Medicaid members.

Effect on executive leadership and governance

The lawsuit has raised serious questions about Centene’s leadership:

• Sarah London stepped in as CEO, replacing longtime leader Michael Neidorff
• Settlement agreements might force governance reforms
• The company will face tough questions about its financial guidance and disclosure practices

The legal battle ended up pushing Centene to rethink its approach to transparency, risk management, and how it communicates with investors.

Conclusion

Centene Corporation stands at a critical point as the $1.25 billion class action lawsuit moves forward. Investors need to act fast to safeguard their interests before the  deadline for lead plaintiff motions.

The case against Centene shows several serious issues. The company made misleading claims about their revenue and growth forecasts. They kept quiet about unfavorable Medicare enrollment numbers and didn’t tell investors about rising market morbidity trends.

The legal battle has just started, but the damage is clear. The company’s stock price crashed by 40% overnight, which wiped out billions in shareholder value. Morgan Stanley downgraded Centene’s stock on top of growing worries about Medicaid and Commercial segments.

There’s still hope for shareholders who bought Centene securities between December 12, 2024, and June 30, 2025. Law firms now take cases without upfront fees on a contingency basis. Investors must keep detailed records of their transactions to get any money back.

This goes beyond just money – it questions how transparent and accountable healthcare companies should be. The final ruling will change how Centene handles its financial reports, manages risks, and runs its business.

The ongoing legal fight creates more uncertainty for Centene while it deals with complex healthcare rules and market challenges. The company might need big changes in how it operates and who leads it to win back investor trust and find stable ground in the market.

Frequently Asked Questions about the Centene Lawsuit

Q1. What is the Centene lawsuit about? The lawsuit alleges that Centene Corporation misled investors about its financial projections, Medicare enrollment data, and market morbidity trends, leading to significant losses when the truth was revealed.

Q2. Who is eligible to join the Centene lawsuit? Investors who purchased Centene securities between December 12, 2024, and June 30, 2025, and suffered financial losses as a result of the alleged misconduct are eligible to join the lawsuit.

Q3. What is the deadline for filing a lead plaintiff motion in the Centene lawsuit? The deadline for filing a lead plaintiff motion in the Centene class action lawsuit is September 8, 2025.

Q4. How did Centene’s stock price react to the allegations? Centene’s stock price collapsed by over 40% in a single day, dropping from $56.65 per share to $33.78 per share when the company withdrew its 2025 financial guidance.

Q5. What are the potential consequences for Centene beyond the lawsuit? Beyond the lawsuit, Centene may face reputational damage, loss of investor confidence, potential financial penalties, and possible changes in executive leadership and governance practices.